MSKCC Oncology Fellow, Former Vanderbilt MSTP/UCLA Intern. Bass player in the CheckPoints. Physician-scientist studying metabolism. Views are my own! 🏳️‍🌈🩺

Manhattan, NY
Joined February 2012
Dr. Brad Reinfeld, MD PhD retweeted
🧬 NICHE-2 | Phase II | dMMR colon cancer 🇳🇱 👥 111 pts | Nivo + ipi → surgery 🎯 3-y DFS 100% 📈 5-y OS 100% 🩸 ctDNA clearance 82% pre-op ✅ All ctDNA− post-op ⚠️ Single-arm trial 💡 Remarkable long-term outcomes! 🔗 doi.org/10.1016/S0140-6736(2… @OncoAlert
3
29
3
67
6,098
Dr. Brad Reinfeld, MD PhD retweeted
97% risk reduction for composite outcome!
1
2
2
22
6,277
Dr. Brad Reinfeld, MD PhD retweeted
🥼Scientists have developed a massively parallel single-cell #CRISPR screening platform in primary human #hematopoietic stem and progenitor cells, capturing known associations and functional annotation of regulator-phenotype relationships. Read more in @CellStemCell: bit.ly/4dLvplB.
8
24
1,592
Dr. Brad Reinfeld, MD PhD retweeted
New #JITC article: "Site-specific metabolic and hypoxia-associated profiles in metastatic melanoma" doi.org/10.1136/jitc-2026-01…
2
2
3
576
Dr. Brad Reinfeld, MD PhD retweeted
Drs. Jennifer Marvin-Peek & Farhad Ravandi summarize the evolving therapeutic landscape of #AML, including current intensive and lower-intensity treatment backbones, approved molecularly targeted therapies, and emerging investigational strategies. 💊 bit.ly/4dI8nMo | @SpringerNature #OpenAccess #AcuteMyeloidLeukemia
1
7
434
Dr. Brad Reinfeld, MD PhD retweeted
After many years of effort, deliberation, excitement, angst, joy, and Wednesday afternoon lab lunches, our group's first manuscript on cachexia, led by Venise Jan Castillon, Amy Xie, and really our whole lab nature.com/articles/s41591-0… @NatureMedicine
9
42
5
128
15,582
Dr. Brad Reinfeld, MD PhD retweeted
New @jclinicalinvest study led by @BraunMDPhD @YaleCancer and super star Dr Madsen : HIF-2α inhibition with belzutifan preserves T-cell effector function in ccRCC—supporting the rationale for combining HIF-2α and PD-1 blockade without compromising T-cell activity. Reassuring translational evidence! jci.org/articles/view/204613
6
27
2
82
6,387
Dr. Brad Reinfeld, MD PhD retweeted
There is growing evidence that Nectin-4 expression matters for EV/P response. We discuss new data linking Nectin-4 expression with treatment outcomes—and what this could mean for biomarker-driven use of EV/P. Delighted to collaborate with @niklas_kluemper @Markuseckstein3 @DrRosenbergMSK on this @EUplatinum editorial. Read it here: authors.elsevier.com/c/1ntqg…
11
36
2,122
Dr. Brad Reinfeld, MD PhD retweeted
T-cell numbers may matter less than their neighborhood. ICI-responsive melanoma was not simply richer in activated lymphocytes. The distinguishing feature was spatial organization: clonally expanded CD8⁺ tumor-resident T cells, CD4⁺ resident T cells and DC3 dendritic cells assembled into local immune triads found only in responding tumors. TCF1⁺ progenitor-like resident CD8⁺ cells were also enriched, suggesting these niches may continuously replenish cytotoxic effectors rather than merely host terminally activated cells. The counterpoint is equally interesting. Resistant tumors still carried strong IFN-γ programs, but alongside exhaustion and an immunosuppressive macrophage state. So an “inflamed” tumor is not necessarily an effective one. The relevant variable may be whether inflammation is organized into a functional local circuit connecting dendritic cells, helper T cells and renewable cytotoxic T cells. The study is associative—32 lymph-node metastases included only six ICI responders—and cannot establish that these triads cause response. But it argues that spatial immune architecture may be a more informative biomarker than T-cell abundance or IFN-γ signaling alone. #immunotherapy #T_cell #Australia nature.com/articles/s41467-0…
14
78
5,833
Tomorrow at #IMS26: MSK myeloma specialist @UrviShahMD will present research on targeting a metabolic-epigenetic axis to improve CAR T therapy in multiple myeloma. @Myeloma_Society 🗓️ Saturday, September 26 | 11 a.m. BT / 6 a.m. ET
1
6
1
31
4,641
Dr. Brad Reinfeld, MD PhD retweeted
Aaron Viny, MD (@TheDoctorIsVin) was diagnosed with acute lymphoblastic leukemia (ALL) at age 20. More than two decades later, Dr. Viny is a physician-scientist, leukemia specialist, and researcher at Columbia, where the questions he once faced as a patient now influence the therapies he provides and the research he leads. columbiamed.link/4iFNogD
1
3
11
1,046
Dr. Brad Reinfeld, MD PhD retweeted
Big news - Jehovah’s Witnesses can receive PRBC, platelets FFP etc if they want jw.org/en/global-communicati…
4
41
9
154
51,772
Dr. Brad Reinfeld, MD PhD retweeted
Incredibly excited to report today on the determinants of toxicity to systemic therapy in cancer patients. Led by many including Alex Guo, Feiyang Huang, Saksham Mohan, River Walser, and the fearless @ZiadBakouny. Co-led by Wes Tansey and Jian Carrot-Zhang medrxiv.org/content/10.64898…
1
18
4
59
14,152
Dr. Brad Reinfeld, MD PhD retweeted
Out in @Cancer_Cell: TET2 inhibition reprograms myeloid cells to potentiate radiotherapy and curb metastasis sciencedirect.com/science/ar… @rweichselbaum @UChicagoRadonc @UChicagoMed @Ludwig_Cancer @hhmi_science
1
3
17
1,764
Dr. Brad Reinfeld, MD PhD retweeted
Important U.S. label update for tarlatamab (IMDELLTRA) in ES-SCLC. For the first 2 doses (C1D1 + C1D8), monitoring is now 6–8 h from start of infusion — reduced from 22–24 h. Next-day assessment + vital signs are required on Days 2 and 9.
4
17
37
2,361